SEC Form 4 · accession 0000313143-15-000077

HAEMONETICS CORP · HAE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Global Human Resources

Period of report

Jul 21, 2015

Accepted (ET)

Aug 11, 2015 · 6:29 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000313143

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 21, 2015	A	2,679	$0.00	A	2,679	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F2	$39.1908	Jul 21, 2015	A	27,404	A	Jul 21, 2016	Jul 21, 2022	Common Stock	27,404	27,404	D
Performance Shares^F3	$0.00	Jul 21, 2015	A	11,250	A	Sep 30, 2017	Dec 31, 2017	Common Stock	11,250	11,250	D

F1Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
F2Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
F3Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Company?s stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d)..